Progyny (NASDAQ:PGNY) vs. Zhongchao (NASDAQ:ZCMD) Head to Head Contrast

Progyny (NASDAQ:PGNY) and Zhongchao (NASDAQ:ZCMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Progyny has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Zhongchao has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500.

Institutional & Insider Ownership

94.9% of Progyny shares are held by institutional investors. Comparatively, 1.7% of Zhongchao shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 28.6% of Zhongchao shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Progyny and Zhongchao’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Zhongchao	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and target prices for Progyny and Zhongchao, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0	3	8	2	2.92
Zhongchao	1	0	0	0	1.00

Progyny currently has a consensus price target of $34.36, indicating a potential upside of 33.76%. Given Progyny’s stronger consensus rating and higher possible upside, equities analysts clearly believe Progyny is more favorable than Zhongchao.

Earnings and Valuation

This table compares Progyny and Zhongchao”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.31 billion	1.50	$58.52 million	$0.92	27.92
Zhongchao	$11.37 million	0.09	-$6.31 million	N/A	N/A

Progyny has higher revenue and earnings than Zhongchao.

Summary

Progyny beats Zhongchao on 12 of the 13 factors compared between the two stocks.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About Zhongchao

Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.